Migraine Drugs Market

Migraine Drugs Market Size:

The global migraine drugs market size reached US$ 4.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.3 Billion by 2032, exhibiting a growth rate (CAGR) of 4.3% during 2024-2032. The global migraine drugs market growth is significantly driven by the increasing assimilation of migraines, expanding knowledge of treatment processes, the development of therapies like CGRP-based drugs, the promotion of preventive treatments, and the rising expansion opportunities in emerging markets.

Migraine Drugs Market Analysis:

• Major Market Drivers: The increasing incidence of migraines worldwide is the crucial factor for the significant growth in migraine drugs market share. The rise in recognition of the disease and the option for treatment is fueling the high demand for migraine medicines. Moreover, the rise of research and development activities by the main actors focusing on the development of healthier treatments such as CGRP treatment is having a positive effect on the market trend.
• Key Market Trends: The migraine drug market trends include the increasing focus on preventive medications and the improvements in treatment pathways. Strategic actions of market players, for instance, new product launches and partnerships, have escalated the number of therapies and innovations in the field.
• Geographical Trends: North America dominates the migraine drugs market due to the presence of key players, supportive reimbursement policies, and a focus on precision medicine in the region. The widespread rise of migraines and the growing focus on improving patient outcomes are other factors that contribute to the expansion of the market in this region.
• Competitive Landscape: Some of the major market players in the migraine drugs industry include Abbott Laboratories, Allergan Plc (Abbvie Inc.), Amgen Inc., AstraZeneca Plc, Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals), Eisai Co. Ltd., Eli Lilly and Company, Endo International Plc, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Limited, among many others.
• Challenges and Opportunities: The market faces challenges including the emergence of the side effects of medicines and the strict rules and regulations. Moreover, opportunities lie in expanding Asian countries, where the rate of migraine stays high and the development of new, more effective medieval treatments.
   

Migraine Drugs Market Trends:

Increasing Awareness and Diagnosis

The increase in the perception of migraine headaches and their extremely disabling type of outcome has augmented the migraine drugs demand. As for its prevalence, visitors continue to be undiagnosed or undertreated. The primary role of government health agencies, including, for example, the Centers for Disease Control and Prevention (CDC), is to instruct people about migraines resulting in the increased number of sick individuals who seek medical support. Additionally, as more people become aware of the necessity for efficient treatments, they also contribute to the demand for treatments, which fuels the market growth. According to the CDC, there is approximately 20% of women and 9% of man who are suffering from migraines in the United States. It is a significant percentage of the population. This increasing appreciation of migraines as a significant health matter promotes both migraine patients and healthcare professionals to search for the most prospective migraine treatment variation.

Advancements in Drug Development

Ongoing improvement in scientific and drug development drives the migraine drugs market revenue. In the pharmaceutical sector, the research and development of innovative treatments for migraine sufferers present one of the important workloads. This involves the use of medications that are superior in efficacy, safety, and administration modes, including the use of new delivery systems or drug formulations. According to the National Institutes of Health (NIH) data, over 100 clinical trials associated with migraine treatment are currently ongoing, which only strengthens the view that the research community is hot on the heels in search of the treatment. Every discovery opens a new market niche in which different options are becoming available for patients, and the treatment becomes better, improving the living conditions of migraineurs people.

Rising Healthcare Expenditure

The rising healthcare expenditure around the world is creating a positive migraine drug market outlook. The governments and the private methods are concentrating more and more funds on the prevention and reduction of diseases like migraines which are known to imminently affect healthcare systems and society. As per the World Health Organization (WHO), worldwide healthcare spending has been experiencing a constant trend of expansion, largely to deal with chronic disease management conditions. As a result, these people gain easier access to the healthcare industry services and cures, escalating the demand for migraine medicine. This pattern is the most prominent in the emerging markets, in which migraines are getting more widespread and this in turn provides specific avenues for pharmaceutical companies in terms of the therapies and interventions they provide for managing the symptoms of migraines.

Migraine Drugs Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on treatment type, drug type, route of administration, and distribution channel.

Breakup by Treatment Type:

• Abortive Treatment
• Preventive Treatment 
   

Preventive treatment accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the treatment type. This includes abortive treatment and preventive treatment. According to the report, preventive treatment represented the largest segment.

Preventive dominates the migraine drugs market as it has proved to help reduce the frequency and intensity of migraine attacks, thereby improving the quality of life of the patients. As per the reports of the National Institutes of Health (NIH), 38% of migraineurs in the United States are looking for preventive treatment, whereas only a marginal section of them receives it. The former emphasizes the coherent unmet necessity for preventive methods. Driven by the fact that migraines are constant and that the best medicine against them is a preventative one, there has been an increasing trend among doctors and patients to use preventive medications for acute cases. So, this growing trend requires preventive approaches as the core of migraine management.

Breakup by Drug Type:

• Triptans
• Ergot Alkaloids
• NSAIDs
• Acetylcholine Inhibitors/ Neurotoxins
• Ditans
• CGRP mAbs
• Others
   

Triptans hold the largest share of the industry

A detailed breakup and analysis of the market based on the drug type have also been provided in the report. This includes triptans, ergot alkaloids, NSAIDs, acetylcholine inhibitors/neurotoxins, ditans, CGRP mAbs, and others. According to the report, triptans accounted for the largest market share.

Based on the migraine drugs market forecast, triptans leads the market as migraine drugs are rooted in their ability to provide speedy relief from migraine symptoms, with special emphasis on headaches, neck pain, nausea as well as sensitivity to light and noise. For instance, as per the reports of the National Institute of Neurological Disorders and Stroke (NINDS) triptans, which has the highest prescription rate in the US, is the class of medication most commonly used by doctors for acute migraine treatment in the United States. They exert their effect by exciting sympathetic fibers in the blood vessels and by obstructing the passage of pain signals to the brain. With more than 20% of women and 9% of men with migraine experience in the U.S., there is still critical inpatient care gaps in effective acute treatments like triptans. Their growing popularity and widespread acceptance among healthcare providers prove their place in the migraine drugs market for acute attacks treatment, allowing patients trust their abilities to relieve pain.

Breakup by Route of Administration:

• Oral
• Injectable
• Others
   

Oral represents the leading market segment 

The report has provided a detailed breakup and analysis of the market based on the route of administration. This includes oral, injectable, and others. According to the report, oral represented the largest segment.

Oral route of administration drives the migraine drugs market value due to the convenience and ease of use of oral medications that allow patients to self-administer the treatment at home or on the go without medical supervision. According to the National Institute of Neurological Disorders and Stroke (NINDS), oral medications are the most frequently used treatment for migraine by healthcare providers. Its oral formulation also results in a faster onset of action compared to other routes, which facilitates relief for patients who are amid an acute migraine attack. Due to the existence of migraines among 20% of US women and 9% of men, there has been a rise in demand for oral treatments. The accessibility and effectiveness of these treatments make the dominance of the oral drug route applicable to the migraine drugs market.

Breakup by Distribution Channel:

• Hospital-Based Pharmacies
• Retail Pharmacies
• Others
   

A detailed breakup and analysis of the market based on the distribution channel have also been provided in the report. This includes hospital-based pharmacies, retail pharmacies, and others.

Hospital-based pharmacies are hospital-based and are situated in hospitals, offering medicinal products and pharmaceutical services to inpatients and outpatients. In the migraine drugs markets, hospital-based pharmacies play a vital role in making emergency departments or outpatient clinics accessible to acute migraine treatment patients. They have an expanded variety of medications in stock, that include triptans and other substances that are specific to the treatment of migraine. This ensures quick access and administration to acute migraine patients.

Retail pharmacies are pharmacies that are located in commercial and residential neighborhoods and offer prescription and over-the-counter drugs to the public. Alongside retail pharmacies, migraine patients who need both acute and preventive treatments turn to these pharmacies to access their drugs as it is a key point of care. They render counseling and support to patients, which is important for the correct usage of medicines and strict follow-up of treatment regimens. As retail pharmacies offer convenience that, they are emerging as key players in the distribution and availability of migraine medications by taking care of the migraine sufferers, even in distinct communities around.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

North America leads the market, accounting for the largest migraine drugs market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represented the largest market for migraine drugs.

North America dominates the market due to the high prevalence of diseases in the area, whereas the region boasts of a robust healthcare infrastructure and high healthcare spending, which form the backbone for market growth. Based on data from the U.S National Institute of Neurological Disorders and Stroke (NINDS), one out of every 10 Americans have migraines. Apart from that, North America has several big pharmaceutical companies that mainly deal with the development of anti-migraine drugs therefore setting up an environment that allows for research and product development. In addition, efforts by government agencies such as the US Food and Drug Administration (FDA) to ensure the speed of approval of drugs for the treatment of migraines also contribute to the region’s market spreading. As a result, these forces keep North America at the top level of the worldwide migraine drugs industry.

Competitive Landscape:

• The migraine drugs market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the migraine drugs industry include Abbott Laboratories, Allergan Plc (Abbvie Inc.), Amgen Inc., AstraZeneca Plc, Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals), Eisai Co. Ltd., Eli Lilly and Company, Endo International Plc, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer Inc., Sanofi SA and Teva Pharmaceutical Industries Limited.
  
  (Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
   
• The key players in the migraine drugs market are constantly working on the research and development and commercialization stages and aim at fulfilling the needs of the migraine sufferers. Pharmaceutical concerns such as Amgen, Eli Lilly, and Teva Pharmaceutical Industries are among the industry players that are promoting cutting-edge therapies, for instance, calcitonin gene-related peptide (CGRP) inhibitors and gepants, for both treatment of acute migraines and prophylaxis. For instance, as per the migraine drugs market research U.S. National Institutes of Health (NIH) reports that the companies are currently enrolling participants for trials whose purpose is to evaluate the drugs for their safety and efficacy. The development of these respective initiatives, the rising of awareness about migraines in general, and access to proper treatment are also among the priorities of these companies. 

Migraine Drugs Market News:

• In February 2022, Biohaven Pharmaceutical and Pfizer revealed positive top-line results with a Phase 3 clinical trial, which was conducted in the Asia-Pacific region and aimed to determine rimegepant's effectiveness in the option of migraine treatment. This study demonstrated effective and safe rimegepant application for pregnant migraine and its associated symptoms. Rimegepant, a tiny molecule targeting calcitonin gene-related peptide (CGRP) receptors, proved to be effective in ending acute migraine attacks speedily. The data ascertains a momentous step in migraine sufferers’ therapeutic accessibility progress in the Asian national region, which could potentially lead to regulatory approval of rimegepant.
• In January 2022, BioDelivery Sciences introduced Elyxyb (celecoxib oral solution) which is pioneering in the field of migraine treatment. It is among the highly effective adult ready-to-use oral solutions approved by the Food and Drug Administration (FDA) as a quick remedy for acute migraine attacks either with or without aura. Elyxyb's formulation comes in a liquid form, which makes its application fast and easy for the patients, thus providing them with an efficient approach to stop the symptoms of migraines. The introduction of this novel product reflects the company's effort and concern toward migraine patients, who had inadequate treatment methods at their disposal in the past, now this new product offers them the chance to improve their quality of life significantly.

Migraine Drugs Market Report Scope:

Key Questions Answered in This Report:

• How has the global migraine drugs market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global migraine drugs market?
• What is the impact of each driver, restraint, and opportunity on the global migraine drugs market?
• What are the key regional markets?
• Which countries represent the most attractive migraine drugs market?
• What is the breakup of the market based on the treatment type?
• Which is the most attractive treatment type in the migraine drugs market?
• What is the breakup of the market based on the drug type?
• Which is the most attractive drug type in the migraine drugs market?
• What is the breakup of the market based on the route of administration?
• Which is the most attractive route of administration in the migraine drugs market?
• What is the breakup of the market based on the distribution channel?
• Which is the most attractive distribution channel in the migraine drugs market?
• What is the competitive structure of the market?
• Who are the key players/companies in the global migraine drugs market?

Key Benefits for Stakeholders:

• IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the migraine drugs market from 2018-2032.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the global migraine drugs market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the migraine drugs industry and its attractiveness.
• The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.